Colorectal cancer (CRC) is a leading tumor worldwide. In CRC, the angiogenic pathway plays a crucial role in cancer development and the process of metastasis. Thus, anti-angiogenic drugs represent a milestone for metastatic CRC (mCRC) treatment and lead to significant improvement of clinical outcomes. Nevertheless, not all patients respond to treatment and some develop resistance. Therefore, the identification of predictive factors able to predict response to angiogenesis pathway blockade is required in order to identify the best candidates to receive these agents. Unfortunately, no predictive biomarkers have been prospectively validated to date. Over the years, research has focused on biologic factors such as genetic polymorphisms, circulating biomarkers, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and microRNA. Moreover, research efforts have evaluated the potential correlation of molecular biomarkers with imaging techniques used for tumor assessment as well as the application of imaging tools in clinical practice. In addition to functional imaging, radiomics, a relatively newer technique, shows real promise in the setting of correlating molecular medicine to radiological phenotypes.
结直肠癌是全球范围内主要的恶性肿瘤之一。在结直肠癌中，血管生成通路在癌症发展和转移过程中起着关键作用。因此，抗血管生成药物已成为转移性结直肠癌治疗的重要里程碑，显著改善了临床疗效。然而，并非所有患者都对治疗产生反应，部分患者还会产生耐药性。因此，需要识别能够预测血管生成通路阻断治疗反应的预测因子，以筛选最适合接受此类药物治疗的患者。遗憾的是，迄今为止尚未有预测性生物标志物经过前瞻性验证。多年来，研究重点集中在遗传多态性、循环生物标志物、循环肿瘤细胞、循环肿瘤DNA以及微小RNA等生物学因素上。此外，研究还评估了分子生物标志物与肿瘤评估影像学技术之间的潜在关联，以及影像学工具在临床实践中的应用。除了功能成像外，放射组学作为一种相对较新的技术，在将分子医学与放射学表型相关联方面展现出巨大潜力。
肿瘤(癌症)患者之家